Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Dolby Laboratories, Inc. (DLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Dolby Laboratories, Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $280 (market cap $39.89B), while Dolby Laboratories, Inc. trades at $50 (market cap $4.71B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 8.5× Dolby Laboratories, Inc.'s market cap, and Dolby Laboratories, Inc. pays a 2.83% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | DLB | |
|---|---|---|
Market Cap | $39.89B | $4.71B |
Sector | Health | Industrials |
52-Week High | $491.22 | $76.79 |
52-Week Low | $278.09 | $49.31 |
Enterprise Value | $38.15B | $4.17B |
Dividend Yield | — | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
DLB trades at $49.8, down 0.64% on the day, with a bearish technical outlook but strong fundamentals. Recent earnings beats, including Q1 2026 EPS of $1.37 versus $1.31 expected, highlight operational strength. The company maintains high gross margins of 87.44% and positive cash flow, supported by licensing growth and expanding Dolby Atmos adoption.
The stock presents a value opportunity with a P/E of 19.76 below historical averages, and a consensus price target of $87.50 implies significant upside. Risks include cyclical end-market exposure and potential dilution from pipeline developments. Analyst sentiment is moderately bullish, but technical indicators suggest near-term pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Dolby Laboratories, Inc.
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Read more on DLB →
